The efficacy of ketogenic interventions on neuropsychological & metabolic outcomes in serious mental illness & neurocognitive disorders: a systematic review & meta-analysis

Ketogenic interventions have garnered attention for their potential benefits in individuals with psychiatric and neurocognitive disorders. This review analyzed findings from studies investigating the impact of ketogenic interventions on clinical outcomes in individuals with serious mental illness (SMI) and neurocognitive disorders. A comprehensive search was conducted to identify studies reporting on psychopathology or cognitive performance in individuals with schizophrenia spectrum, major mood, mild cognitive impairment (MCI), or major neurocognitive disorders/dementia treated with a ketogenic intervention. Changes in body composition, metabolic parameters, adherence, and safety were also assessed. Evidence was organized by population and outcome of interest, and supplemented by a quantitative meta-analysis. Seventy-three studies (SMI k = 31; neurocognitive disorders k = 42) were included, with treatment durations ranging from single-dose interventions up to 12 years. Evidence in SMI was largely limited to case reports and single-arm trials reporting symptom remission, reductions in positive and negative symptoms, and mood improvements. Controlled trials in neurocognitive disorders provided more substantiated evidence amenable to meta-analysis. Ketogenic interventions improved cognitive performance (SMD 0.24, 95% CI [0.06, 0.43], p = 0.01, n = 587, k = 14, I² = 61%) and reduced body weight (MD − 3.13 kg, 95% CI [−5.91, −0.35], p = 0.03, n = 80, k = 3, I² = 6%) in this population. Gastrointestinal symptoms were the most frequently reported adverse event. While the evidence for ketogenic interventions differs by population, promising findings emerge. In neurocognitive disorders, controlled trial data support modest cognitive and metabolic benefits. In SMI, preliminary evidence highlights the evolving nature of this field and the need for more rigorous investigation, including RCTs, to establish clinical safety and efficacy.

Authors

Institutions

Publication Details

Journal
Translational Psychiatry
Published
2026-08-27
DOI
https://doi.org/10.1038/s41398-026-04370-2
Primary Topic
Diet and metabolism studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The efficacy of ketogenic interventions on neuropsychological & metabolic outcomes in serious mental illness & neurocognitive disorders: a systematic review & meta-analysis

Ana C. Andreazza, Cameron Arnold, Reena Besa, Riddhita De et al.
Translational Psychiatry
Diet and metabolism studies
article

The efficacy of ketogenic interventions on neuropsychological & metabolic outcomes in serious mental illness & neurocognitive disorders: a systematic review & meta-analysis

Ana C. Andreazza, Cameron Arnold, Reena Besa, Riddhita De, Margaret Hahn, Kateryna Maksyutynska, Sri Mahavir Agarwal, Kristoffer Panganiban, Bjørn Hylsebeck Ebdrup, Stephen C. Cunnane, Kevin Zemmour, Bailey Humber, Nicolette Stogios, Tin Heng Mak, Emily CC. Smith
article en

Abstract

Ketogenic interventions have garnered attention for their potential benefits in individuals with psychiatric and neurocognitive disorders. This review analyzed findings from studies investigating the impact of ketogenic interventions on clinical outcomes in individuals with serious mental illness (SMI) and neurocognitive disorders. A comprehensive search was conducted to identify studies reporting on psychopathology or cognitive performance in individuals with schizophrenia spectrum, major mood, mild cognitive impairment (MCI), or major neurocognitive disorders/dementia treated with a ketogenic intervention. Changes in body composition, metabolic parameters, adherence, and safety were also assessed. Evidence was organized by population and outcome of interest, and supplemented by a quantitative meta-analysis. Seventy-three studies (SMI k = 31; neurocognitive disorders k = 42) were included, with treatment durations ranging from single-dose interventions up to 12 years. Evidence in SMI was largely limited to case reports and single-arm trials reporting symptom remission, reductions in positive and negative symptoms, and mood improvements. Controlled trials in neurocognitive disorders provided more substantiated evidence amenable to meta-analysis. Ketogenic interventions improved cognitive performance (SMD 0.24, 95% CI [0.06, 0.43], p = 0.01, n = 587, k = 14, I² = 61%) and reduced body weight (MD − 3.13 kg, 95% CI [−5.91, −0.35], p = 0.03, n = 80, k = 3, I² = 6%) in this population. Gastrointestinal symptoms were the most frequently reported adverse event. While the evidence for ketogenic interventions differs by population, promising findings emerge. In neurocognitive disorders, controlled trial data support modest cognitive and metabolic benefits. In SMI, preliminary evidence highlights the evolving nature of this field and the need for more rigorous investigation, including RCTs, to establish clinical safety and efficacy.

Translational Psychiatry
University of Copenhagen (DK), Centre for Addiction and Mental Health (CA), Université de Sherbrooke (CA), University of Toronto (CA), Glostrup Hospital (DK)
Good health and well-being
Openalex Percentile: Top 10%
Diet and metabolism studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.